{"title":"印度子宫内膜异位症患者服用新型缓释地屈孕酮与传统制剂的疗效和安全性比较多中心 III 期研究","authors":"T. Sasikala, Shikha Kushwaha, Mukta Agarwal, Vandana Jain, Deepti Bawa, Suchitra Narayan, Pavankumar Daultani, Ashok Jaiswal, Monika Chinda, Anit Singh","doi":"10.18203/2320-1770.ijrcog20241298","DOIUrl":null,"url":null,"abstract":"Background: The aim of the study was to compare the efficacy and safety of novel once-daily extended-release (ER) dydrogesterone 20 mg versus conventional twice-daily dydrogesterone 10 mg in Indian patients with endometriosis.\nMethods: A phase III prospective, randomized, double-blind, single-dummy, two-arm, active-controlled, parallel, multicenter study was performed in six gynecology centers across India. The patients of 18 to 45 years of age with a confirmed diagnosis of endometriosis on ultrasonography (USG) and having endometriosis-associated pelvic pain score (EAPP) of at least 30 mm on a 100 mm visual analog scale (VAS) were randomly assigned to a 1:1 ratio to either once-daily dydrogesterone ER 20 mg or twice-daily dydrogesterone 10 mg arms for a treatment period of 90 days. The primary outcome was a change from baseline in EAPP score at the end of the treatment.\nResults: A total of 228 patients with a mean age of 31.8±6.9 years were enrolled in the study. At day 90, both the treatment arms showed a significant reduction (p<0.05) in EAPP score from baseline (i.e. -34.2±15.3 mm and -33.1±14.8 mm in once daily dydrogesterone ER and twice daily dydrogesterone 10 mg, respectively), with no significant difference between the two arms (p=0.53). With both formulations, patients experienced a significant reduction in the size of endometrioma, serum vascular endothelial growth factors (VEGF) levels, use of rescue analgesics, and significant improvement in the health-related quality-of-life parameters. A favorable safety profile of dydrogesterone was confirmed, and no significant safety concerns were reported during the study.\nConclusions: Once daily dydrogesterone ER 20 mg and twice daily dydrogesterone 10 mg demonstrated a significant and similar reduction in EAPP and all other secondary parameters along with marked improvements in parameters related to quality of life.","PeriodicalId":14225,"journal":{"name":"International journal of reproduction, contraception, obstetrics and gynecology","volume":"63 14","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A multicentre phase III study comparing efficacy and safety of novel extended-release versus conventional formulation of dydrogesterone in Indian patients with endometriosis\",\"authors\":\"T. Sasikala, Shikha Kushwaha, Mukta Agarwal, Vandana Jain, Deepti Bawa, Suchitra Narayan, Pavankumar Daultani, Ashok Jaiswal, Monika Chinda, Anit Singh\",\"doi\":\"10.18203/2320-1770.ijrcog20241298\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: The aim of the study was to compare the efficacy and safety of novel once-daily extended-release (ER) dydrogesterone 20 mg versus conventional twice-daily dydrogesterone 10 mg in Indian patients with endometriosis.\\nMethods: A phase III prospective, randomized, double-blind, single-dummy, two-arm, active-controlled, parallel, multicenter study was performed in six gynecology centers across India. The patients of 18 to 45 years of age with a confirmed diagnosis of endometriosis on ultrasonography (USG) and having endometriosis-associated pelvic pain score (EAPP) of at least 30 mm on a 100 mm visual analog scale (VAS) were randomly assigned to a 1:1 ratio to either once-daily dydrogesterone ER 20 mg or twice-daily dydrogesterone 10 mg arms for a treatment period of 90 days. The primary outcome was a change from baseline in EAPP score at the end of the treatment.\\nResults: A total of 228 patients with a mean age of 31.8±6.9 years were enrolled in the study. At day 90, both the treatment arms showed a significant reduction (p<0.05) in EAPP score from baseline (i.e. -34.2±15.3 mm and -33.1±14.8 mm in once daily dydrogesterone ER and twice daily dydrogesterone 10 mg, respectively), with no significant difference between the two arms (p=0.53). With both formulations, patients experienced a significant reduction in the size of endometrioma, serum vascular endothelial growth factors (VEGF) levels, use of rescue analgesics, and significant improvement in the health-related quality-of-life parameters. A favorable safety profile of dydrogesterone was confirmed, and no significant safety concerns were reported during the study.\\nConclusions: Once daily dydrogesterone ER 20 mg and twice daily dydrogesterone 10 mg demonstrated a significant and similar reduction in EAPP and all other secondary parameters along with marked improvements in parameters related to quality of life.\",\"PeriodicalId\":14225,\"journal\":{\"name\":\"International journal of reproduction, contraception, obstetrics and gynecology\",\"volume\":\"63 14\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-05-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International journal of reproduction, contraception, obstetrics and gynecology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.18203/2320-1770.ijrcog20241298\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of reproduction, contraception, obstetrics and gynecology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18203/2320-1770.ijrcog20241298","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
研究背景该研究旨在比较新型每日一次缓释(ER)地屈孕酮 20 毫克与传统每日两次地屈孕酮 10 毫克在印度子宫内膜异位症患者中的疗效和安全性:在印度的六个妇科中心开展了一项 III 期前瞻性、随机、双盲、单剂量、双臂、主动对照、平行、多中心研究。经超声波检查(USG)确诊为子宫内膜异位症且子宫内膜异位症相关盆腔疼痛评分(EAPP)在100毫米视觉模拟量表(VAS)上至少达到30毫米的18至45岁患者,按1:1的比例随机分配到每天一次的地屈孕酮ER 20毫克或每天两次的地屈孕酮10毫克治疗组,治疗期为90天。主要结果是治疗结束时EAPP评分与基线相比的变化:共有 228 名患者参加了研究,平均年龄(31.8±6.9)岁。在第 90 天,两种治疗方案的 EAPP 评分均比基线显著降低(p<0.05)(即每日一次地屈孕酮 ER 为 -34.2±15.3 mm,每日两次地屈孕酮 10 mg 为 -33.1±14.8 mm),两种治疗方案之间无显著差异(p=0.53)。使用这两种制剂后,患者的子宫内膜异位瘤大小、血清血管内皮生长因子(VEGF)水平、止痛药使用量均显著减少,与健康相关的生活质量参数也明显改善。研究证实,地屈孕酮具有良好的安全性,在研究过程中未出现重大安全问题:结论:每日一次的地屈孕酮 ER 20 毫克和每日两次的地屈孕酮 10 毫克可显著降低 EAPP 和所有其他次要参数,并明显改善与生活质量相关的参数。
A multicentre phase III study comparing efficacy and safety of novel extended-release versus conventional formulation of dydrogesterone in Indian patients with endometriosis
Background: The aim of the study was to compare the efficacy and safety of novel once-daily extended-release (ER) dydrogesterone 20 mg versus conventional twice-daily dydrogesterone 10 mg in Indian patients with endometriosis.
Methods: A phase III prospective, randomized, double-blind, single-dummy, two-arm, active-controlled, parallel, multicenter study was performed in six gynecology centers across India. The patients of 18 to 45 years of age with a confirmed diagnosis of endometriosis on ultrasonography (USG) and having endometriosis-associated pelvic pain score (EAPP) of at least 30 mm on a 100 mm visual analog scale (VAS) were randomly assigned to a 1:1 ratio to either once-daily dydrogesterone ER 20 mg or twice-daily dydrogesterone 10 mg arms for a treatment period of 90 days. The primary outcome was a change from baseline in EAPP score at the end of the treatment.
Results: A total of 228 patients with a mean age of 31.8±6.9 years were enrolled in the study. At day 90, both the treatment arms showed a significant reduction (p<0.05) in EAPP score from baseline (i.e. -34.2±15.3 mm and -33.1±14.8 mm in once daily dydrogesterone ER and twice daily dydrogesterone 10 mg, respectively), with no significant difference between the two arms (p=0.53). With both formulations, patients experienced a significant reduction in the size of endometrioma, serum vascular endothelial growth factors (VEGF) levels, use of rescue analgesics, and significant improvement in the health-related quality-of-life parameters. A favorable safety profile of dydrogesterone was confirmed, and no significant safety concerns were reported during the study.
Conclusions: Once daily dydrogesterone ER 20 mg and twice daily dydrogesterone 10 mg demonstrated a significant and similar reduction in EAPP and all other secondary parameters along with marked improvements in parameters related to quality of life.